Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Shares Outstanding (Diluted Average) (2022 - 2025)

PAVmed (PAVM) has 4 years of Shares Outstanding (Diluted Average) data on record, last reported at $17.9 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) changed N/A year-over-year to $17.9 million; the TTM value through Sep 2025 reached $17.9 million, changed N/A, while the annual FY2024 figure was $65.3 million, 802.87% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $17.9 million in Q3 2025 per PAVM's latest filing, down from $54.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $89.8 million in Q3 2022 and bottomed at $5.9 million in Q4 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $32.1 million, with a median of $9.2 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Diluted Average): tumbled 92.25% in 2023, then skyrocketed 802.87% in 2024.
  • A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $5.9 million in 2022, then rose by 21.78% to $7.2 million in 2023, then surged by 802.87% to $65.3 million in 2024, then tumbled by 72.64% to $17.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $17.9 million in Q3 2025, $54.3 million in Q2 2025, and $52.5 million in Q1 2025.